Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 301

IP Group unveils mid-year results

IP Group supplied less funding to its portfolio companies but witnessed a three-fold increase in cash realisations during the first half of 2019.

Sep 10, 2019

Noske notches up an Alliance Ventures promotion

Ex-GCV Rising Star Christian Noske will head up the Renault-Nissan-Mitsubishi unit, less than two years after joining from BMW i Ventures.

Sep 10, 2019

Parkwalk Opportunities EIS pours $65m into spinouts

Spinouts such as Oxford’s Moa Technology and Cambridge’s Paragraf were a focal point for Parkwalk Advisors’ largest EIS-assisted venture fund during the 2018-19 tax year.

Sep 9, 2019

Volocopter reaches first close of series C

The Intel and Daimler-backed air taxi developer secured $55.2m in a tranche led by Geely Holding and intends to reach a final close later this year.

Sep 9, 2019

Eggleston leaves BGF for Pantheon

John Eggleston has departed from his position as head of the tech sector for BGF in order to take up the chief technology officer role at Pantheon Ventures.

Sep 9, 2019

Corporate venturing deal net: 2-6 September 2019

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Sep 6, 2019

Gyroscope spins to series B round

Gyroscope Therapeutics, a dry AMD treatment developer exploiting University of Cambridge research, has secured $61.2m from cornerstone investors Cambridge Innovation Capital and Syncona.

Sep 4, 2019

DMGT drives Cazoo's latest round

Existing investor DMG Ventures has returned to back a $30.4m round for automotive e-commerce platform Cazoo, its second in nine months.

Sep 4, 2019

Investors slip $23m to Elliptic

SBI Group and Santander InnoVentures backed a series B round that boosted cryptocurrency security tool developer Elliptic's funding to $30m altogether.

Sep 4, 2019

Caldan calls in $2.4m

Leveraging University of Glasgow and University of Southern Denmark research, Caldan is targeting a free fatty acid receptor associated with fatty liver disease and type 2 diabetes.

Sep 4, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here